C5 Antibody (Monoclonal)
A murine monoclonal antibody to an epitope on C5.
Product Specifications
Citations | 9 |
---|---|
Clonality | Monoclonal |
Immnogen | Purified human protein. |
Applications | See citations and technical data sheet for application info. |
Concentration | 1.0-1.2 mg/mL |
Conjugate | Unconjugated |
Cross Reactivity | Human, Baboon |
Ordering Information
Catalog Number | A217 |
---|---|
Catalog Number (CE) | N/A |
Size | 100 µl |
Price (USD) | $365.00 |
Price (EURO) | 330,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description | A murine monoclonal antibody to an epitope on C5. |
---|---|
Size | 100 µl |
Concentration | 1.0-1.2 mg/mL |
Applications | See citations and technical data sheet for application info. |
Form | Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide. |
Clonality | Monoclonal |
Immunogen | Purified human protein. |
Conjugate | Unconjugated |
Cross Reactivity | Human, Baboon |
Isotype | IgG1k |
Purity | ≥ 95% by SDS PAGE |
Source | Mouse |
Specificity | This monoclonal antibody was raised against purified human C5. It is specific for an antigen expressed on the C5 but not on MAC Complex. This antibody inhibits the lysis of EA and will not bind to MAC bound to a membrane. |
Storage | Short term (30 days) 4˚C. Long term at or below –20˚C. |
Background | Complement protein, C5 is unique to the Terminal Complement Pathway. The C5 protein is composed of two subunits (Alpha – 115,000 kD and Beta – 75,000 kD) and is present in serum at a concentration of approximately 70 mg/L. Under normal conditions, activation of either the Classical, Lectin or Alternative Complement Pathways generates the C5 convertase which is capable of cleaving C5 into two fragments – C5a (a potent anaphylatoxin) and C5b. Together with other proteins of the Terminal Pathway, C5b forms the Membrane Attack Complex (MAC) or Terminal Complement Complex (TCC) at the surface of a target cell; resulting in cell lysis. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2019 | Complement Activation Assay | Human | B-Cells | N/A | |
2019 | ELISA | Human | Plasma | N/A | |
2019 | ELISA | Human | Serum | N/A | |
2019 | WB | Human | Plasma | Chronic Lymphocytic Leukemia | |
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. | 2015 | FC | Cell Culture | HAEC Cells | N/A |
Activation of complement system in kidney after ketoprofen-induced kidney injury in sheep | 2015 | IHC | Human | Kidney Tissue | N/A |
2014 | Complement Activation Assay | Human | Serum | N/A | |
2011 | ELISA | Human | Serum | N/A | |
Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells | 2002 | FC | Hamster | CHO Cells | MCP Transfected |